Why Semaglutide Dominates Globally

Why Semaglutide Dominates Globally: Key Benefits and Popularity

Semaglutide mimics the GLP-1 hormone to:

Improve glycemic control in type 2 diabetes (reducing HbA1c by ~1.5%).

Promote significant, sustained weight loss.

Reduce cardiovascular risks and improve outcomes in related conditions like kidney disease.

Why Semaglutide Dominates Globally

Its popularity exploded due to the global obesity crisis—affecting over 1 billion adults and rising diabetes rates. In high-income countries, off-label and approved use for weight management has driven massive demand.

The World Health Organization (WHO) recognized this in late 2025 by issuing its first global guideline on GLP-1 therapies (including semaglutide, liraglutide, and tirzepatide) for obesity treatment. It describes obesity as a "chronic, relapsing disease" and conditionally recommends long-term GLP-1 use (at least 6 months) in adults (excluding pregnant women), combined with lifestyle changes like diet, exercise, and behavioral support.

In September 2025, WHO added these agents to its Essential Medicines List for high-risk type 2 diabetes patients (e.g., those with CVD or obesity), signaling strong global endorsement despite access barriers.

Global Market Size and Usage Statistics 2025–2026

The semaglutide market has seen explosive growth, fueled by diabetes and obesity epidemics.

Market value — Valued at approximately USD 28–31 billion in 2024–2025, projections show it reaching USD 34–35 billion in 2025 and climbing to USD 59–93 billion by 2033–2035 (CAGR 10–12%).

Key drivers Rising prescriptions for weight loss (even without diabetes), label expansions (e.g., cardiovascular benefits, potential MASH approval), and easing supply shortages.

Usage trends — In the US (largest market), GLP-1 use among adults with diabetes hit high rates, with semaglutide leading. Real-world data shows millions using it; one estimate notes ~13.5 million active GLP-1 users (including semaglutide) in the US by mid-2025.

Regional insights 

North America holds 46% share, but Asia-Pacific grows fastest due to diabetes prevalence.

Challenges persist: High costs ($700–1,000/month in high-income countries) limit access, with WHO estimating fewer than 10% of eligible people globally can afford or obtain these therapies by 2030. Equity remains a major issue.

Semaglutide in Pakistan: Availability, Pricing, and Local Trends

Pakistan faces one of the world's highest diabetes burdens (~26–33 million affected), making semaglutide highly relevant.

Availability Imported brands (Ozempic, Wegovy) are available, but local generics have surged. Companies like Searle launched oral semaglutide (Rybelsus-like) in 2025, with injectables following. Domestic production of GLP-1s (including semaglutide) began in late 2025, improving supply.

Pricing (2025–2026)  Imported Ozempic pens: ~PKR 27,000–28,000 per pen. Local generics: Much more affordable—e.g., oral SemO 3mg (14 tablets) ~PKR 2,450; 7mg ~PKR 4,550. Injectable generics launched at competitive prices like PKR 8,800 for a month's supply (4 doses).

Market growth  From niche to billions in PKR value by 2025, with oral forms boosting accessibility over injections.

Patent impact  Semaglutide patents expire in key markets like India and China in 2026 (March), potentially slashing prices 50–80% via generics, similar to trends in Pakistan.

As a pharmacist , you've likely seen rising inquiries for diabetes control and weight loss. Always prioritize DRAP-approved use, monitor GI side effects (nausea common initially), teach injection/oral technique, and emphasize diet/exercise.

Future Outlook: Challenges and Opportunities

Semaglutide's global revolution continues into 2026 with:

Patent expiries enabling cheaper generics in populous markets.

New formulations (e.g., oral semaglutide expansions).

Competition from dual/triple agonists (tirzepatide, etc.).

However, equitable access, long-term safety data, and misuse prevention remain key. Pharmacists are frontline in education, adherence support, and combating off-label trends without proper oversight.

Semaglutide isn't just a drug—it's reshaping chronic disease care worldwide. In Pakistan, falling prices and local production could make it a true game-changer for millions.

Have you dispensed semaglutide recently? What's the most common patient question in your pharmacy? Drop a comment below—let's share experiences!

(Updated February 2026. Sources: WHO 2025 guidelines, market reports from Grand View Research, ResearchAndMarkets, IQVIA, local pharma news like Haq's Musings and Bloomberg. Consult DRAP and latest prescribing info for Pakistan use.